跳至主要内容
临床试验/NCT02673606
NCT02673606已完成1 期

The Influence of Estrogen on the Fear Extinction Network in Humans-R61

NYU Langone Health1 个研究点 分布在 1 个国家目标入组 136 人开始时间: 2013年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
136
试验地点
1
主要终点
Impact of exogenous administration of estradiol on the neural correlates of fear extinction

研究概览

简要总结

The goal of this project is to examine how estrogen may influence the resting-state connectivity and the extinction-induced activation of the fear extinction network.

详细描述

The aim of the study was to examine the influence of exogenous estrogen administration on the activation of the fear extinction network in women. Functional MRI data and psychophysiological indices were collected to test the influence of estrogen on women's ability to regulate conditioned fear responses. Women underwent a 3 day experimental paradigm using classical fear conditioning. The first day was conducted outside the scanner, while days 2 and 3 were done inside the fMRI scanner and tested fear extinction learning and recall in days 2 and 3, respectively. The estrogen (or placebo) pill was given just hours before extinction learning test on day 2. No followups were conducted after women completed the 3 day study.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Double (Participant, Investigator)

盲法说明

double blind placebo control study

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Right-handed (Edinburgh Inventory - Oldfield 1971).
  • SCID diagnosis consistent with none, current or past history of Axis I psychiatric disorders.
  • To be matched for age, gender, and years of education, as well as self-identified race/ethnicity.
  • For naturally cycling female subjects, stage of menstrual cycle will be ascertained by history, and by serological measures.
  • For women on oral contraceptives, we will identify those using 20mcg ethinyl, 2nd or 3rd generation, monophasic

排除标准

  • Psychiatric, neurologic or medical condition that would interfere with study procedures or confound results, ascertained by history.
  • History of seizure or significant head trauma (i.e., extended loss of consciousness, neurological sequelae, or known structural brain lesion).
  • History of Axis I psychiatric diagnosis; e.g., history of substance use disorder, psychotic disorder, bipolar disorder, tic disorder, or eating disorder.
  • Use of psychotropic medication within 4 weeks prior to study (within 6 weeks for fluoxetine, or other long-lived compounds; within one year for neuroleptics).
  • Pregnancy (to be ruled out by urine ß-HCG).
  • Metallic implants or devices contraindicating magnetic resonance imaging.
  • Use of oral contraceptives or non-oral contraceptives containing estrogen and progesterone within 3 months
  • History of breast cancer.
  • Allergy to peanut oil.

研究组 & 干预措施

Estradiol 4mg Dose

Experimental

4mg dose of estradiol (oral administration)

干预措施: Estradiol 4Mg Tablet (Drug)

Placebo

Placebo Comparator

placebo (oral administration)

干预措施: Placebo Pills (Drug)

Estradiol 2mg Dose

Experimental

2mg dose of estradiol (oral administration)

干预措施: Estradiol 2Mg Tablet (Drug)

结局指标

主要结局

Impact of exogenous administration of estradiol on the neural correlates of fear extinction

时间窗: 3 Days

BOLD responses during fear extinction after taking estradiol or placebo

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验